Polomar 10-Q: Q3 Revenue $1.13M, Restatement Adds $490K to Losses, Going Concern Doubt
PMHS sits 92% above its 52-week low of $0.065 on light trading volume (0.3× avg).
Summary
Polomar grew Q3 revenue to $1.13M but lost $513,550, quantified a $490,433 restatement of its first-half 2026 results, and repeated substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · PMHS
-
Q3 Revenue Jumps to $1.13M
Revenue rose to $1,133,775 for the three months ended September 30, 2026 from $6,163 a year earlier, driven by prescription fulfillment volume; nine-month revenue was $3,739,944.
-
Quarterly Loss of $513,550
Net loss was $513,550 for Q3 2026 and $829,002 for the nine months, with gross margin at 45.4%.
-
Restatement Adds $490,433 to Losses
Corrections increased net loss by $393,551 for Q1 2026 and $96,882 for Q2 2026, a total of $490,433 for the six months ended June 30, 2026; amended 10-Q/As are still to be filed.
-
Going Concern Doubt Reaffirmed
Management cited $254,779 of cash and a $14,565,652 accumulated deficit as raising substantial doubt about the ability to continue as a going concern for one year.
Analysis · PMHS · Life Sciences
Polomar's first full quarter of commercial pharmacy operations generated $1,133,775 in revenue, up from $6,163 a year earlier, yet the company still lost $513,550 in the quarter and $829,002 over nine months. Hard numbers now attach to the restatement first flagged on November 3: correcting unrecorded commissions, expenses booked to inventory, mis-timed revenue and the preferred stock classification added $393,551 to the Q1 2026 net loss and $96,882 to Q2, $490,433 in total. Management also reaffirmed substantial doubt about continuing as a going concern — $254,779 of cash against a $14,565,652 accumulated deficit — and said the material weaknesses that caused the errors were not remediated as of September 30. The related-party Profesco note held by Interim CEO Tierney has been in default since January 1, 2026 and now accrues 18%.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMHS was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.